Eric Rose, CMO knows prospects. He is buying. We'll see more insiders buying soon. I've topped up with an intention to sell at $2/s. GLTAH
"Mesoblast intends to file the resubmission this quarter, potentially resulting in an approval for
Ryoncil® (remestemcel-L) in the second half of CY2024. "
Source: APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED MARCH 31, 2024
Ann: Appendix 3Y for Eric Rose, page-29
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |